Page 1

INVITAE Exhibit 99.1 Invitae to Acquire Ciitizen to Strengthen its Patient - Consented Health Data Platform to Improve Personal Outcomes and Global Research Ciitizen platform will empower patients to securely collect , organize and benefit from their full range of health data - - Combination to bring together the power of genomic and clinical information within a new kind of patient data platform to improve healthcare decision making at personal and systemwide levels ― Hosting Conference Call and Webcast for investors today at 8:30 a.m. ET / 5:30 a.m. PT — SAN FRANCISCO , September 7 , 2021 — Invitae ( NYSE : NVTA ) , a leading medical genetics company , today announced it has entered into a definitive agreement to acquire Ciitizen , a patient - centric consumer health tech company . Backed by a16z , Section 32 and Verily , Ciitizen is working to build a global platform to help patients collect , organize , store and share their medical records digitally . The acquisition would enhance Invitae's platform by providing patients an easy - to - use , centralized hub for their genomic and clinical information , which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making . " Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe . We believe combining Ciitizen's state - of - the - art , transparent and patient - consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one's life . This would give us the ability to engage patients , create an innovative patient - centered data ecosystem and deliver better outcomes for everyone . Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing , software and health information technology spaces , " said Sean George , Ph.D. , co - founder and CEO of Invitae . " Ciitizen has already helped patients take ownership of their medical records to optimize therapy for themselves and contribute their data towards a variety of goals , including research on rare diseases , " said Anil Sethi , CEO and founder of Ciitizen . " Patients leave a breadcrumb trail of records behind them , and we believe access to this real - world data is key to personalized therapeutics in the future . The combination of lifelong health history together with Invitae's world - class genetic and data services would enable a digital ecosystem of personalized services for each patient . Democratization of patient - consented data is expected to improve outcomes by providing access to third - parties for whom the patient has granted consent . Unlike many health data companies , we operate on the premise that it's the patient's data , not ours . " Dr. George continued , “ Genomics is currently a laboratory testing - based industry , but in the future it will look very much like an information industry . Developing an open - ended patient - centric platform of genomic , clinical and 1